HBIO
Harvard Bioscience
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 3
consensus rating "Strong Buy"
Price Hits 52-week low
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About HBIO
Harvard Bioscience, Inc.
A developer of life sciences equipment to support research and drug discovery
Life Science Tools and Services
Invalid Date
12/07/2000
NASDAQ Stock Exchange
330
12-31
Common stock
84 October Hill Road, Holliston, Massachusetts 01746
--
Harvard Bioscience, Inc., was incorporated in Delaware in 1901. The Company is a leading developer, manufacturer and marketer of technologies, products and services that enable fundamental progress in life science applications, including research, pharmaceutical and therapeutic discovery, biological production, and preclinical testing for pharmaceutical and therapeutic development.
Company Financials
EPS
HBIO has released its 2024 Q4 earnings. EPS was reported at 0.06, versus the expected 0.05, beating expectations. The chart below visualizes how HBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HBIO has released its 2024 Q4 earnings report, with revenue of 24.56M, reflecting a YoY change of -12.78%, and net profit of 18.00K, showing a YoY change of 100.99%. The Sankey diagram below clearly presents HBIO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
